Related Experiment Video
Updated: Mar 5, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
New Therapeutic Strategies in Acute Lymphocytic Leukemia
Louise M Man1, Amy L Morris2, Michael Keng3
1Division of Hematology/Oncology, University of Virginia Health System, 1300 Jefferson Park Avenue, Room 6023, PO Box 800716, Charlottesville, VA, 22903, USA.
Abstract:
Most drugs used in standard regimens for acute lymphoblastic leukemia (ALL) were developed more than 30 years ago. Since that time, several new drugs have been developed and incorporated into ALL treatment. In spite of this, novel therapeutic approaches are still needed to improve outcomes for high-risk or relapsed ALL. This manuscript discusses newer treatment strategies, including purine nucleoside analogs, monoclonal antibodies, antibody drug conjugates, mammalian target of rapamycin (mTOR) inhibitors, proteasome inhibitors, histone deacetylase (HDAC) inhibitors, hypomethylating agents, spleen tyrosine kinase inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors, anti-programmed cell death protein (anti-PD-1) antibodies, mitogen-activated protein kinase (MEK) inhibitors, CXCR4 antagonists, poly (ADP-ribose) polymerase (PARP) inhibitors, and FMS-like tyrosine kinase 3 (FLT3) inhibitors. Additionally, this manuscript discusses the impact of diagnostic approaches on management of ALL. Specifically, minimal residual disease is increasingly felt to be important and will likely dramatically impact the care of ALL patients in the near future.
Insights
Novel therapies are crucial for high-risk acute lymphoblastic leukemia (ALL) treatment. This review covers emerging drugs and diagnostic tools like minimal residual disease monitoring to improve patient outcomes.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Standard acute lymphoblastic leukemia (ALL) treatments rely on older drugs, necessitating new approaches.
- Despite advancements, high-risk and relapsed ALL patients require improved therapeutic strategies.
Purpose of the Study:
- To review novel therapeutic agents and diagnostic advancements in acute lymphoblastic leukemia (ALL) management.
- To highlight the potential impact of emerging treatments on improving outcomes for challenging ALL cases.
Main Methods:
- Comprehensive review of recent literature on novel drug classes for ALL.
- Discussion of the role of diagnostic techniques, particularly minimal residual disease (MRD) detection.
Main Results:
- Numerous novel drug classes show promise, including targeted therapies like tyrosine kinase inhibitors and immunotherapies such as monoclonal antibodies.
- Advancements in diagnostic approaches, especially minimal residual disease (MRD) monitoring, are poised to significantly influence ALL patient care.
Conclusions:
- Emerging targeted therapies and immunotherapies offer new hope for acute lymphoblastic leukemia (ALL) patients.
- Minimal residual disease (MRD) assessment will likely play a pivotal role in tailoring future ALL treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
02:56Treatment Resistant Cancers